Email this article Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors
- Authors: Chapoval A.I.1,2, Chapoval S.P.3, Shcherbakova N.S.1,4, Shcherbakov D.N.1,4
-
Affiliations:
- Russian-American Anti-Cancer Center, Altai State University
- The Biodesign Institute, Center for Innovation in Medicine, Arizona State University
- Department of Microbiology and Immunology, Center for Vascular and Inflammatory Diseases, Program in Oncology, Greenebaum Cancer Center, University of Maryland School of Medicine
- FSRI SRC VB Vector, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
- Issue: Vol 45, No 5 (2019)
- Pages: 321-334
- Section: Review Article
- URL: https://journals.rcsi.science/1068-1620/article/view/229213
- DOI: https://doi.org/10.1134/S1068162019050091
- ID: 229213
Cite item
Open Access
Access granted
Subscription Access
Abstract
Immune checkpoints regulate polarity, strength, and termination of the immune response. The leading roles in these processes are played by molecules of the B7 family. Based on data obtained using first representatives of the B7 family molecules, a two-signal model for T cells activation was proposed. The discovery of new homologues of B7-1 and B7-2 molecules revealed not only a great variety of their structural organization, but also new functions, for example the B7-H6 molecule is able to activate NK cells through interaction with NKp30 molecule. Manipulations of the B7 ligands and their interactions with specific receptors provide opportunities for fine tuning of the immune response against various pathogens and development of new drugs. The second part of this review provides information on recently discovered representatives of the B7 family, such as B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, ILDR2, and their receptors.
About the authors
A. I. Chapoval
Russian-American Anti-Cancer Center, Altai State University; The Biodesign Institute, Center for Innovation in Medicine, Arizona State University
Author for correspondence.
Email: andreichapoval@gmail.com
Russian Federation, Barnaul, 656049; Tempe, AZ 85281
S. P. Chapoval
Department of Microbiology and Immunology, Center for Vascular and Inflammatory Diseases, Program in Oncology, Greenebaum Cancer Center, University of Maryland School of Medicine
Email: andreichapoval@gmail.com
United States, Baltimore, MD, 21201
N. S. Shcherbakova
Russian-American Anti-Cancer Center, Altai State University; FSRI SRC VB Vector, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: andreichapoval@gmail.com
Russian Federation, Barnaul, 656049; Koltsovo, Novosibirsk oblast, 630559
D. N. Shcherbakov
Russian-American Anti-Cancer Center, Altai State University; FSRI SRC VB Vector, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: andreichapoval@gmail.com
Russian Federation, Barnaul, 656049; Koltsovo, Novosibirsk oblast, 630559
